Cancer Res (2026) 86 (5_Supplement_2): A010.

Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...

You do not currently have access to this content.

Background: KRAS is a key mediator of the RAS/MAPK signaling cascade and promotes cellular growth and proliferation. It is the most frequently mutated oncogene in cancer, and KRAS G12C mutations occur ...

Abstract. A key barrier to effective immunotherapy for cancer is the immunosuppressive tumor microenvironment (TME) characterized by infiltrating regulatory T cells (Tregs) and myeloid-derived ...

De novo pyrimidine synthesis is a universal requirement for cancer cell proliferation; however, targeting this pathway results in toxicity to all dividing cells. The rate limiting conversion of UTP to ...

Abstract. Brentuximab vedotin (ADCETRIS®) is an antibody-drug conjugate (ADC) directed against CD30. It consists of an anti-CD30 monoclonal antibody conjugated to monomethyl auristatin E (MMAE), a ...

Abstract. TGFβ may act as a tumor suppressor early in tumorigenesis; however, TGFβ is also known to support tumor growth via multiple mechanisms, including promotion of epithelial-mesenchymal ...

Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex Open Access Linjie Yuan; Wenzhi Ji; Brendan G. Dwyer; Joey Lu; Jing Bian; ...

Cancer Epidemiol Biomarkers Prev (2009) 18 (6): 1740–1745. The U.S. active-duty military population may differ from the U.S. general population in its exposure to cancer risk factors and access to ...

Mol Cancer Ther (2023) 22 (12_Supplement): PR010. Methods: Patients with previously treated, advanced KRAS G12X mutant solid tumors were enrolled at escalating doses of single agent RMC-6236 ...

Department of Bio-therapeutic, The First Medical Center, Chinese PLA General Hospital (Medical School of Chinese PLA), Beijing, China.